NOBILIS RHINO CV

Main information

  • Trade name:
  • NOBILIS RHINO CV
  • Pharmaceutical form:
  • Powder for nebuliser solution
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • NOBILIS RHINO CV
    France
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • Avian rhinotracheitis virus vaccine
  • Therapeutic area:
  • Chicken

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • FR/V/0151/001
  • Authorization date:
  • 02-04-2010
  • EU code:
  • FR/V/0151/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

NobilisRhinoCV

ES:NobilisRT11/94;IT:Nobilis ® RTCV1194;AT,DE:NobilisRhino

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Activesubstance:

Perdosemin.10 1.5 TCID

andmax.10 3.7 TCID

ofliveattenuatedavianrhinotracheitisvirusstrain11/94.

Foralistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Lyophilisateforsuspensionforoculonasalorsprayapplication.

4. CLINICALPARTICULARS

4.1 Targetspecies

Chicken.

4.2 Indicationsforuse,specifyingthetargetspecies

Forbroilers,futurelayersandbreedersfromonedayofage.

Broilers,futurelayersandbreeders

Activeimmunisationinordertoreducethefrequencyandtheseverityofclinicalsignsduetoinfectionwith

avianrhinotracheitisvirus(avianmetapneumovirus).Theonsetofimmunityis3weeksandthedurationof

immunityis16weekspost-vaccination.

Futurelayersandbreeders

PrimingwithNobilisRhinoCV,followedbyasecondvaccinationwithaninactivatedvaccinecontainingthe

avianrhinotracheitisvirusstrainBut1#8544beforetheonsetoflayresultsinareductionoftheclinicalsigns

includingeggdrop,causedbyinfectionwithavianrhinotracheitisvirus.Protectiveimmunityismaintainedfor

thenormallayingperiod.

4.3 Contraindications

None.

4.4 Specialwarnings

None.

TissueCultureInfectiveDose50%

4.5 Specialprecautionsforuse

Specialprecautionsforuseinanimals

Onlyvaccinatehealthybirds.

Inordertoreducethecirculationofthevaccinestrain,allsusceptibleanimalsonthesitehavetobe

vaccinatedproperlyandpreferablyatthesametime.Thevaccineviruscanspreadtoothersusceptible

specieswithwhichtheyhavedirectcontact.Itwasshownthatthespreadinghasnegligibleimpacton

turkeys,whichtogetherwithchickensconstitutethespeciesthataremostsusceptibletoavianrhinotracheitis

virus.

Specialprecautionstobetakenbythepersonadministeringtheveterinarymedicinalproductto

animals

Notapplicable.

4.6 Adversereactions(frequencyandseriousness)

Inalowpercentageofflocks(lessthan10%),vaccinationcanleadtoslightnasaldischargeorcoughingby

somebirdsbetween2to7daysafteradministrationfor1to2days.

4.7 Useduringlay

Donotuseinbirdsinlayand/orwithin4weeksbeforetheonsetofthelayingperiod.

4.8 Interactionwithothermedicinalproductsandotherformsofinteraction

Safetyandefficacydataareavailablewhichdemonstratethatthisvaccinecanbeadministeredonthesame

daybutnotmixedwithvaccinesagainstinfectiousbronchitiscontainingstrainH120andagainstNewcastle

diseasecontainingstrainsClone30orC2andinfectiousbronchitisvaccine(strainIBMa5)whengivenon

day1(theefficacyoftheIBMa5vaccinehasnotbeeninvestigated).

Intervet’slivevaccineagainstGumborodisease(infectiousbursaldisease)containingtheD78straincanbe

given7daysafterNobilisRhinoCV.

Noinformationisavailableonthesafetyandefficacyofthisvaccinewhenusedwithanyotherveterinary

medicinalproductexcepttheproductsmentionedabove

Adecisiontousethisvaccinebeforeorafteranyotherveterinaryproductthereforeneedstobemadeona

casebycasebasis.

4.9 Amountstobeadministeredandadministrationroute

Oculonasaladministrationviaeye-ornose-dropmethodorviacoarsespray,onedoseperbirdfrom1dayold.

Oculonasalroute

Reconstitutethefreeze-driedvaccineinclean,disinfectant-andantiseptic-freewatertowhich2%liquid

skimmedmilkisaddedandadministerbymeansofastandardiseddropper.Theamountoffluidrequiredfor

eye-ornose-dropadministrationdependsonthenumberofdosesandthedropletsize,butapproximately35

mlper1000dosesisused.Applyonedropinanareoreye.Checkthatthedropisentirelyabsorbedbefore

releasingthebird.

Sprayvaccination

Thevaccinemustbereconstitutedwithclean,disinfectant-andantiseptic-freewatertowhich2%ofliquid

skimmedmilkisadded.Theappropriatenumberofvialsmustbeopenedunderwater.Thevolumeofvaccine

suspensionmustbesufficienttoensureahomogeneousvaccinationofthebirds.

Dependingontheageofthechickenstobevaccinatedandtherearingsystem,take250to500mlofwater

per1000doses.Thevaccinesuspensionistobesprayedevenlyovertheappropriatenumberofanimalsata

distanceof30-40cmwitharegularsprayingapparatus,preferablywhentheanimalssittogetherunderadim

light.Thesprayapparatusmustbefreefromsediments,corrosionandtracesofdisinfectantsandideally

shouldbeusedforvaccinationpurposesonly.

Ifapplicable,reduceventilationtopreventlossofspray.

Forfuturelayersandbreederspleaseseesection4.2.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Administrationoftenfoldthemaximumdosebytherecommendedrouteshasnotresultedinanyothereffect

onthetargetspeciesthanthosedescribedunder4.6.

4.11Withdrawalperiod

Zerodays.

5. IMMUNOLOGICALPROPERTIES

Thevaccinecontainstheliveattenuatedstrain11/94ofavianrhinotracheitisvirus,sub-typeB.Upon

administration,thevaccineinducesactiveimmunityinchickensagainstavianrhinotracheitisvirus.

ThegrowthcharacteristicofthevaccinestraininChickenEmbryoFibroblastsallowsdifferentiationfrom

fieldvirus.Indicativeresultscanbeobtainedbyspecialisedlaboratories.

ATCVetcode:QI01AD01.AvianRhinotracheitisvirusvaccine.

6. PHARMACEUTICALPARTICULARS

6.1 Listofexcipients

Pancreaticdigestofcasein,Sorbitol,Gelatine,Disodiumphosphatedihydrate,Waterforinjections

6.2 Incompatibilities

Donotmixwithanyothermedicinalproduct.

6.3 Shelflife

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale:2years.

Shelf-lifeafterreconstitutionaccordingtodirections:2hours.

6.4 Specialprecautionsforstorage

Storeinarefrigerator(+2°Cto+8°C).

Donotfreeze

Keepthevialintheoutercartoninordertoprotectfromlight.

6.5 Natureandcompositionofimmediatepackaging

Cardboardboxcontaining1,2,5,10,20or50glass(TypeI)vialsof250,500,1000,2500,5,000,10,000or

25,000dosesclosedwithahalogenobutylrubberstopperandsealedwithanaluminiumcap.

Notallpacksizesmaybemarketed.

6.6 Specialprecautionsforthedisposalofunusedveterinarymedicinalproductsorwaste

materialsderivedfromtheuseofsuchproducts

Disposeofwastematerialbyboiling,incinerationorimmersioninanappropriatedisinfectantinaccordance

withnationalrequirements.

7. MARKETINGAUTHORISATIONHOLDER

IntervetInternationalBV.

WimdeKörverstraat35

5831ANBoxmeer

TheNetherlands

asrepresentedbythenationalcompanies

8. MARKETINGAUTHORISATIONNUMBER

9. DATEOFFIRSTAUTHORISATION/RENEWALOFTHEAUTHORISATION

FR:17June2004/23March2010

10. DATEOFREVISIONOFTHETEXT

February2009

PROHIBITIONOFSALE,SUPPLYAND/ORUSE

Notapplicable.

27-11-2018

FDA warns consumers to avoid Rhino male enhancement products found at retailers because of undeclared and potentially dangerous drug ingredients

FDA warns consumers to avoid Rhino male enhancement products found at retailers because of undeclared and potentially dangerous drug ingredients

FDA issues a warning to consumers to beware of and avoid certain male enhancement products that may be dangerous to their health

FDA - U.S. Food and Drug Administration

22-11-2018

Foreign Product Alert: Black Lion Pill, Help 100% & Pure Natural & Body Slim capsules, Herba Saraf, Horny Little Devil, Ja Dera Max capsules, Lida (Plus) capsules, Nutra Organics Green Tea Extract capsules, Papapa, Red Zone Xtreme 3000, Rhino 69 Extreme 5

Foreign Product Alert: Black Lion Pill, Help 100% & Pure Natural & Body Slim capsules, Herba Saraf, Horny Little Devil, Ja Dera Max capsules, Lida (Plus) capsules, Nutra Organics Green Tea Extract capsules, Papapa, Red Zone Xtreme 3000, Rhino 69 Extreme 5

These foreign health products have been found by regulators in other countries to contain undeclared drug ingredients and/or unacceptable contaminant(s).

Health Canada

22-8-2018

Rhino 8 Platinum 8000 capsules

Rhino 8 Platinum 8000 capsules

Rhino 8 Platinum 8000 capsules pose a serious risk to your health and should not be taken

Therapeutic Goods Administration - Australia

31-7-2018

Public Notification: Black Rhino 25000 contains hidden drug ingredient

Public Notification: Black Rhino 25000 contains hidden drug ingredient

The Food and Drug Administration is advising consumers not to purchase or use Black Rhino 25000, a product promoted for sexual enhancement. This product was identified during an examination of international mail shipments.

FDA - U.S. Food and Drug Administration

31-7-2018

Public Notification: Krazzy Rhino 25000 contains hidden drug ingredient

Public Notification: Krazzy Rhino 25000 contains hidden drug ingredient

The Food and Drug Administration is advising consumers not to purchase or use Krazzy Rhino 25000, a product promoted for sexual enhancement. This product was identified during an examination of international mail shipments.

FDA - U.S. Food and Drug Administration

31-7-2018

Public Notification: Boss Rhino 15000 contains hidden drug ingredient

Public Notification: Boss Rhino 15000 contains hidden drug ingredient

The Food and Drug Administration is advising consumers not to purchase or use Boss Rhino 15000, a product promoted for sexual enhancement. This product was identified during an examination of international mail shipments.

FDA - U.S. Food and Drug Administration

31-7-2018

Public Notification: Gold Rhino 25000 contains hidden drug ingredient

Public Notification: Gold Rhino 25000 contains hidden drug ingredient

The Food and Drug Administration is advising consumers not to purchase or use Gold Rhino 25000, a product promoted for sexual enhancement. This product was identified during an examination of international mail shipments.

FDA - U.S. Food and Drug Administration

31-7-2018

Public Notification: Platinum Rhino 25000 contains hidden drug ingredient

Public Notification: Platinum Rhino 25000 contains hidden drug ingredient

The Food and Drug Administration is advising consumers not to purchase or use Platinum Rhino 25000, a product promoted for sexual enhancement. This product was identified during an examination of international mail shipments.

FDA - U.S. Food and Drug Administration

14-4-2018

'Rhino 69 Extreme 50000' Recalled due to Presence of Active Ingredient 'Tadalafil'

'Rhino 69 Extreme 50000' Recalled due to Presence of Active Ingredient 'Tadalafil'

AMA Wholesale Inc. (Distributor/Re-seller), is voluntarily recalling Rhino 69 Extreme 50000 capsules to the consumer level. FDA analysis found the product to be tainted with undeclared tadalafil. Tadalafil is an active ingredient in a FDA-approved prescription drug that is used for erectile dysfunction.

FDA - U.S. Food and Drug Administration

28-3-2018

Public Notification: Rhino 69 Extreme 50000 contains hidden drug ingredient

Public Notification: Rhino 69 Extreme 50000 contains hidden drug ingredient

The Food and Drug Administration is advising consumers not to purchase or use Rhino 69 Extreme 50000, a product promoted and sold for sexual enhancement on various websites, including www.bonanza.com, and possibly in some retail stores.

FDA - U.S. Food and Drug Administration

There are no news related to this product.